Use of mometasone furoate aqueous nasal spray in the treatment of rhinitis medicamentosa: an experimental study.
OBJECTIVE
We aimed to investigate, histopathologic changes in the nasal mucosa of guinea pig's after prolonged administration of oxymetazoline and the development of rhinitis medicamentosa, and the efficacy of mometasone furoate aqueous nasal spray and saline in reversing the ultrastructural changes attributable to rhinitis medicamentosa.


METHODS
In the study, 24 male guinea pigs (500 to 600 gr) were used. Oxymetazolin (0.05%) was sprayed into the nasal cavities of the guinea pigs 3 times daily for 8 weeks. At the end of this period, 6 guinea pigs were killed and examined to make sure that the animals had developed rhinitis medicamentosa. The remaining guinea pigs were randomly divided into 3 groups. In the first group, one spray-puff of 0.05% mometasone furoate aqueous nasal spray (50 microg) was applied twice daily for 14 days. In the second group, saline solution (0.9% NaCl) was applied twice daily for 14 days. No treatment was performed in the third group. At the end of the treatment period, nasal mucosal changes were evaluated by light microscopy and electron microscopy.


RESULTS
After oxymetazolin application for 8 weeks, the main histologic changes were edema, congestion, proliferation of subepithelial glands, and squamous cell metaplasia. After topical mometasone furoate aqueous spray application for 2 weeks, the edema fluid was found to diminish markedly. In the saline and no treatment groups, edema and congestion continued. In these groups of guinea pigs, fibrosis has been seen in the nasal mucosa.


CONCLUSIONS
We found that mometasone furoate nasal spray was effective against experimentally induced rhinitis medicamentosa in guinea pigs. Mometasone furoate nasal spray may have value in the treatment of patients with rhinitis medicamentosa.
Tas
Abdullah
A
Department of Otolaryngology, Faculty of Medicine, Trakya University, Edirn, Turkey. abdultas@yahoo.com
Yagiz
Recep
R
Yalcin
Omer
O
Uzun
Cem
C
Huseyinova
Gulara
G
Adali
Mustafa K
MK
Karasalihoglu
Ahmet R
AR
D000281:Administration, Intranasal; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D006168:Guinea Pigs; D008297:Male; D008854:Microscopy, Electron; D000068656:Mometasone Furoate; D009297:Nasal Mucosa / Q000187:drug effects / Q000473:pathology; D010109:Oxymetazoline / Q000008:administration & dosage / Q000633:toxicity*; D011244:Pregnadienediols / Q000494:pharmacology*; D012223:Rhinitis, Vasomotor / Q000139:chemically induced* / Q000473:pathology; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000633:toxicity*
D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D014662:Vasoconstrictor Agents; D000068656:Mometasone Furoate; D010109:Oxymetazoline